Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression ≥50%.
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study / Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D.L., Aerts, J.G.J.V., Baldessari, C., Giusti, R., Ferrara, M.G., D'Argento, E., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C., Antonuzzo, L., Mazzoni, F., De Toma, A., Signorelli, D., Gelibter, A., Targato, G., et al.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - STAMPA. - 148:(2021), pp. 24-35. [10.1016/j.ejca.2021.02.005]
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Antonuzzo, Lorenzo;
2021
Abstract
Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression ≥50%.
| File | Dimensione | Formato | |
|---|---|---|---|
|
S0959804921000721.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
844.09 kB
Formato
Adobe PDF
|
844.09 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
